ROQUEFORT THERAPEUTICS PLC Logo

ROQUEFORT THERAPEUTICS PLC

Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.

ROQ | IL

Overview

Corporate Details

ISIN(s):
GB00BMDQ2T15
LEI:
254900P4SISIWOR9RH34
Country:
United Kingdom
Address:
85 Great Portland Street, W1W 7LT London
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Roquefort Therapeutics plc is a biotechnology company focused on developing a portfolio of first-in-class medicines for hard-to-treat cancers. Its pipeline consists of five novel, patent-protected, pre-clinical anti-cancer programs targeting malignancies resistant to existing therapies within the high-growth immuno-oncology market. The company employs a scalable and cost-effective distributed R&D model, combining its in-house, state-of-the-art laboratory capabilities with a network of academic research partnerships. Founded in 2020, Roquefort Therapeutics is led by an experienced team with a proven track record in drug development, regulatory processes, and biotech transactions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 08:00
Capital/Financing Update
Fundraise & Transaction Update
English 16.2 KB
2025-09-08 08:00
M&A Activity
Proposed Acquisition of Clinical Stage Company
English 26.7 KB
2025-07-07 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.3 KB
2025-06-30 08:00
Director's Dealing
Director/PDMR Shareholding
English 24.4 KB
2025-06-27 08:00
M&A Activity
Lyramid SPA Extension
English 14.1 KB
2025-06-26 14:00
Declaration of Voting Results & Voting Rights Announcements
Results of AGM
English 25.0 KB
2025-06-02 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting
English 10.3 KB
2025-05-23 08:00
Capital/Financing Update
Extension of Convertible Loan Notes
English 11.9 KB
2025-05-20 08:50
Annual Report (ESEF)
2024 Annual Report
English 1.8 MB
2025-05-20 08:50
Annual Report
2024 Annual Report
English 3.9 MB
2025-03-14 08:00
Capital/Financing Update
Private Placing and Conversion of CLNs
English 14.5 KB
2025-03-10 08:30
Board/Management Information
Board Changes
English 14.4 KB
2025-03-10 08:00
M&A Activity
Proposed Sale of Oncogeni Ltd
English 13.5 KB
2025-03-04 08:00
Regulatory News Service
Update on Sale of Lyramid
English 15.0 KB
2025-02-04 11:58
Director's Dealing
Director/PDMR Shareholding
English 35.8 KB

Automate Your Workflow. Get a real-time feed of all ROQUEFORT THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ROQUEFORT THERAPEUTICS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ROQUEFORT THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea 149300
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy ABS
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan 246A
Licenses patented material IP (MST®) to create higher-performance, lower-power semiconductors.
United States of America ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan 6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia N/A
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan 6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.